Guardant Health, Inc. (NASDAQ:GH) Director Myrtle S. Potter Sells 2,626 Shares

Guardant Health, Inc. (NASDAQ:GH) Director Myrtle S. Potter sold 2,626 shares of the company’s stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $49.70, for a total transaction of $130,512.20. Following the completion of the transaction, the director now owns 18,180 shares in the company, valued at approximately $903,546. The trade was a 12.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Guardant Health Stock Up 0.0%

NASDAQ GH opened at $49.30 on Tuesday. Guardant Health, Inc. has a 52 week low of $20.14 and a 52 week high of $52.92. The firm has a market capitalization of $6.11 billion, a P/E ratio of -13.85 and a beta of 1.37. The company has a 50-day moving average price of $43.91 and a 200-day moving average price of $41.74.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. During the same quarter in the prior year, the firm earned ($0.46) EPS. The business’s revenue for the quarter was up 20.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Mizuho upped their price target on shares of Guardant Health from $60.00 to $65.00 and gave the stock an “outperform” rating in a research note on Friday. Scotiabank reiterated an “outperform” rating on shares of Guardant Health in a research note on Monday, May 5th. Stephens reiterated an “overweight” rating and issued a $55.00 price target on shares of Guardant Health in a research note on Wednesday, March 26th. Barclays upped their price target on shares of Guardant Health from $55.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, May 1st. Finally, The Goldman Sachs Group boosted their target price on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Twenty-one research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $53.76.

Institutional Investors Weigh In On Guardant Health

Several hedge funds and other institutional investors have recently made changes to their positions in GH. Driehaus Capital Management LLC purchased a new stake in shares of Guardant Health during the 1st quarter valued at about $82,349,000. Invesco Ltd. increased its holdings in Guardant Health by 100.9% in the 1st quarter. Invesco Ltd. now owns 2,794,667 shares of the company’s stock worth $119,053,000 after acquiring an additional 1,403,670 shares in the last quarter. Norges Bank purchased a new stake in Guardant Health in the 4th quarter worth approximately $36,438,000. Two Sigma Advisers LP increased its holdings in Guardant Health by 96.7% in the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock worth $70,742,000 after acquiring an additional 1,138,300 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Guardant Health in the 4th quarter worth approximately $26,673,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.